Drug Shortage Report for ETOPOSIDE INJECTION USP
Report ID | 65767 |
Drug Identification Number | 02380935 |
Brand name | ETOPOSIDE INJECTION USP |
Common or Proper name | ETOPOSIDE |
Company Name | SANDOZ CANADA INCORPORATED |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | ETOPOSIDE |
Strength(s) | 20MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS |
Packaging size | 25ML X 1VIAL |
ATC code | L01CB |
ATC description | PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS |
Reason for shortage | Requirements related to complying with good manufacturing practices. |
Anticipated start date | |
Actual start date | 2018-12-17 |
Estimated end date | 2022-06-27 |
Actual end date | 2022-07-13 |
Shortage status | Resolved |
Updated date | 2022-07-14 |
Company comments | Product is no longer marketed |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 110 RUE DE LAUZON BOUCHERVILLE, QUEBEC CANADA J4B 1E6 |
Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.